Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

Summary

The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal anti-inflammatory drugs (NSAIDs) and/or anti-tumor necrosis factor (TNF) α therapy. Efficacy and safety data were used to support the registration of secukinumab in Japan for the treatment of active AS.

Timeline

Start

2016-03-22

Primary completion

2017-07-05

Completion

2018-05-16

Drugs

Indications